Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T)

Jonathan S. Cebon, Keith Flaherty, Jeffrey S. Weber, Kevin Kim, Jeffrey R. Infante, Adil Daud, Omid Hamid, Richard Kefford, Lynn Mara Schuchter, Jeffrey Alan Sosman, Mario Sznol, William Howard Sharfman, Rene Gonzalez, Miles Cameron Andrews, Roxana Stefania Dronca, Georgina Long, Shonda M. Little, Peng Sun, Kiran Patel, Robert R. McWilliams

Research output: Contribution to journalMeeting abstractpeer-review

Original languageEnglish
Pages (from-to)9016-9016
Number of pages1
JournalJournal of Clinical Oncology
Issue number15 supplement
Publication statusPublished - 20 May 2013
EventAnnual Meeting of the American Society of Clinical Oncology (ASCO) - Chicago, United States
Duration: 31 May 20134 Jun 2013

Cite this